BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liguori C. Orexin and Alzheimer’s Disease. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 305-22. [DOI: 10.1007/7854_2016_50] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Calva CB, Fadel JR. Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res 2020;1731:145921. [PMID: 30148983 DOI: 10.1016/j.brainres.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
2 Targa A, Dakterzada F, Benítez I, López R, Pujol M, Dalmases M, Arias A, Sánchez-de-la-Torre M, Zetterberg H, Blennow K, Pamplona R, Jové M, Barbé F, Piñol-Ripoll G. Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. Sleep 2021;44:zsaa147. [PMID: 32766837 DOI: 10.1093/sleep/zsaa147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Thiyagarajah MT, Herrmann N, Ruthirakuhan M, Li A, Lanctôt KL. Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer’s Disease. Curr Behav Neurosci Rep 2019;6:72-87. [DOI: 10.1007/s40473-019-00181-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Subramanian S, Ravichandran M. Orexin receptors: Targets and applications. Fundam Clin Pharmacol 2021. [PMID: 34464995 DOI: 10.1111/fcp.12723] [Reference Citation Analysis]
5 Wu M, Zhou F, Cao X, Yang J, Bai Y, Yan X, Cao J, Qi J. Abnormal circadian locomotor rhythms and Per gene expression in six-month-old triple transgenic mice model of Alzheimer's disease. Neurosci Lett 2018;676:13-8. [PMID: 29626648 DOI: 10.1016/j.neulet.2018.04.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
6 Li M, Meng Y, Chu B, Shen Y, Xue X, Song C, Liu X, Ding M, Cao X, Wang P, Xu S, Bi J, Xie Z. Orexin-A exacerbates Alzheimer's disease by inducing mitochondrial impairment. Neurosci Lett 2020;718:134741. [PMID: 31927055 DOI: 10.1016/j.neulet.2020.134741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Treu SP, Plante DT. Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis. Sleep Med 2021;85:230-8. [PMID: 34364094 DOI: 10.1016/j.sleep.2021.07.007] [Reference Citation Analysis]
8 Green TRF, Ortiz JB, Wonnacott S, Williams RJ, Rowe RK. The Bidirectional Relationship Between Sleep and Inflammation Links Traumatic Brain Injury and Alzheimer's Disease. Front Neurosci 2020;14:894. [PMID: 32982677 DOI: 10.3389/fnins.2020.00894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sil’kis IG. A Neurochemical Approach to the Search for Drugs for the Treatment of Symptoms of Alzheimer’s Disease. Neurochem J 2018;12:15-22. [DOI: 10.1134/s1819712418010130] [Reference Citation Analysis]
10 Shimizu S, Takenoshita N, Inagawa Y, Tsugawa A, Hirose D, Kaneko Y, Ogawa Y, Serisawa S, Sakurai S, Hirao K, Kanetaka H, Kanbayashi T, Imanishi A, Sakurai H, Hanyu H. Positive Association Between Cognitive Function and Cerebrospinal Fluid Orexin A Levels in Alzheimer’s Disease. JAD 2020;73:117-23. [DOI: 10.3233/jad-190958] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
12 Maestri M, Romigi A, Schirru A, Fabbrini M, Gori S, Bonuccelli U, Bonanni E. Excessive daytime sleepiness and fatigue in neurological disorders. Sleep Breath 2020;24:413-24. [DOI: 10.1007/s11325-019-01921-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
13 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
14 da Luz MHM, Pino JMV, Santos TG, Antunes HKM, Martins VR, de Souza AAL, Torquato RJS, Lee KS. Sleep deprivation regulates availability of PrPC and Aβ peptides which can impair interaction between PrPC and laminin and neuronal plasticity. J Neurochem 2020;153:377-89. [PMID: 31950499 DOI: 10.1111/jnc.14960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020;16:541-51. [PMID: 31944580 DOI: 10.1002/alz.12035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
16 Kong SDX, Hoyos CM, Phillips CL, McKinnon AC, Lin P, Duffy SL, Mowszowski L, LaMonica HM, Grunstein RR, Naismith SL, Gordon CJ. Altered heart rate variability during sleep in mild cognitive impairment. Sleep 2021;44:zsaa232. [PMID: 33306103 DOI: 10.1093/sleep/zsaa232] [Reference Citation Analysis]
17 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
18 Nifli AP. Appetite, Metabolism and Hormonal Regulation in Normal Ageing and Dementia. Diseases 2018;6:E66. [PMID: 30036957 DOI: 10.3390/diseases6030066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Um YH, Lim HK. Orexin and Alzheimer's Disease: A New Perspective. Psychiatry Investig 2020;17:621-6. [PMID: 32517419 DOI: 10.30773/pi.2020.0136] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Winsky-sommerer R, de Oliveira P, Loomis S, Wafford K, Dijk D, Gilmour G. Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: Insights from studies in patient populations and animal models. Neuroscience & Biobehavioral Reviews 2019;97:112-37. [DOI: 10.1016/j.neubiorev.2018.09.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
21 Azeez IA, Igado OO, Olopade JO. An overview of the orexinergic system in different animal species. Metab Brain Dis 2021. [PMID: 34224065 DOI: 10.1007/s11011-021-00761-0] [Reference Citation Analysis]
22 Hopkins K, Mukherjee S, Ponce D, Mangum J, Jacobson LH, Hoyer D. Development of a LC-ESI-MRM method for the absolute quantification of orexin A in the CSF of individual mice. Medicine in Drug Discovery 2021;11:100102. [DOI: 10.1016/j.medidd.2021.100102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li M, Meng Y, Chu B, Shen Y, Liu X, Ding M, Song C, Cao X, Wang P, Xu L, Wang Y, Xu S, Bi J, Xie Z. Orexin-A aggravates cytotoxicity and mitochondrial impairment in SH-SY5Y cells transfected with APPswe via p38 MAPK pathway. Ann Transl Med 2020;8:5. [PMID: 32055596 DOI: 10.21037/atm.2019.11.68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kent BA, Feldman HH, Nygaard HB. Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. Prog Neurobiol 2021;197:101902. [PMID: 32877742 DOI: 10.1016/j.pneurobio.2020.101902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
25 Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology 2020;45:104-20. [PMID: 31408876 DOI: 10.1038/s41386-019-0478-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 78] [Article Influence: 34.7] [Reference Citation Analysis]
26 Cook JD, Ferry DG, Tran KM. Sleep's role in preventing and treating Alzheimer's disease: are we moving towards slow-wave assessment and enhancement? Sleep 2020;43:zsz304. [PMID: 31837225 DOI: 10.1093/sleep/zsz304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Chen XY, Du YF, Chen L. Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease. Front Mol Neurosci 2018;11:493. [PMID: 30687008 DOI: 10.3389/fnmol.2018.00493] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]